SEARCH

SEARCH BY CITATION

References

  • Augustine, C.K., Yoshimoto, Y., Gupta, M., Zipfel, P.A., Selim, M.A., Febbo, P., Pendergast, A.M., Peters, W.P., and Tyler, D.S. (2008). Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res. 68, 37773784.
  • Cavallaro, U., Schaffhauser, B., and Christofori, G. (2002). Cadherins and the tumourprogression: is it all in a switch? Cancer Lett. 176, 123128.
  • Clark Jr, W.H., Elder, D.E., Guerry, D.T., Braitman, L.E., Trock, B.J., Schultz, D., Synnestvedt, M., and Halpern, A.C. (1989). Model predicting survival in stage I melanoma based on tumor progression. J. Natl Cancer Inst. 81, 18931904.
  • Davis, B.N., Hilyard, A.C., Lagna, G., and Hata, A. (2008). SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454, 5661.
  • Divito, K.A., Berger, A.J., Camp, R.L., Dolled-Filhart, M., Rimm, D.L., and Kluger, H.M. (2004). Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res. 64, 87738777.
  • Dwivedi, A., Slater, S.C., and George, S.J. (2009). MMP-9 and -12 cause N-cadherin shedding and thereby beta-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc. Res. 81, 178186.
  • Ebisawa, T., Fukuchi, M., Murakami, G., Chiba, T., Tanaka, K., Imamura, T., and Miyazono, K. (2001). Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. 276, 1247712480.
  • Edlund, S., Lee, S.Y., Grimsby, S., Zhang, S., Aspenstrom, P., Heldin, C.H., and Landstrom, M. (2005). Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. Mol. Cell. Biol. 25, 14751488.
  • Falkson, C.I., Ibrahim, J., Kirkwood, J.M., Coates, A.S., Atkins, M.B., and Blum, R.H. (1998). Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferonalpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 16, 17431751.
  • Guerry, D.T., Synnestvedt, M., Elder, D.E., and Schultz, D. (1993). Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J. Invest. Dermatol. 100, 342S345S.
  • Hazan, R.B., Phillips, G.R., Qiao, R.F., Norton, L., and Aaronson, S.A. (2000). Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J. Cell Biol. 148, 779790.
  • Hendrix, M.J., Seftor, E.A., Chu, Y.W. et al. (1992). Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential. J. Natl Cancer Inst. 84, 165174.
  • Herlyn, M., Berking, C., Li, G., and Satyamoorthy, K. (2000). Lessons from melanocyte development for understanding the biological events in naevus and melanoma formation. Melanoma Res. 10, 303312.
  • Hodi, F.S., Friedlander, P., Corless, C.L. et al. (2008). Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 26, 20462051.
  • Hoover, L.L., and Kubalak, S.W. (2008). Holding their own: the noncanonical roles of Smad proteins. Sci. Signal. 1, pe48.
  • Horner, M.J., Ries, L.A.G., Krapcho, M. et al. (2008). SEER Cancer Statistics Review, 1975–2006 (Bethesda, MD: National Cancer Institute).
  • Hsu, M.Y., Wheelock, M.J., Johnson, K.R., and Herlyn, M. (1996). Shifts in cadherin profiles between human normal melanocytes and melanomas. J. Investig. Dermatol. Symp. Proc. 1, 188194.
  • Hsu, M., Andl, T., Li, G., Meinkoth, J.L., and Herlyn, M. (2000). Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J. Cell Sci. 113(Pt 9), 15351542.
  • Imoto, S., Sugiyama, K., Muromoto, R., Sato, N., Yamamoto, T., and Matsuda, T. (2003). Regulation of transforming growth factor-beta signaling by protein inhibitor of activated STAT, PIASy through Smad3. J. Biol. Chem. 278, 3425334258.
  • Islam, S., Carey, T.E., Wolf, G.T., Wheelock, M.J., and Johnson, K.R. (1996). Expression of N-cadherin by human squamous carcinoma cells induces a scattered fibroblastic phenotype with disrupted cell-cell adhesion. J. Cell Biol. 135, 16431654.
  • Javelaud, D., Delmas, V., Moller, M., Sextius, P., Andre, J., Menashi, S., Larue, L., and Mauviel, A. (2005). Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo. Oncogene 24, 76247629.
  • Javelaud, D., Mohammad, K.S., McKenna, C.R. et al. (2007). Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res. 67, 23172324.
  • Javelaud, D., Alexaki, V.I., andMauviel, A. (2008). Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res 21, 123132.
  • Kohutek, Z.A., diPierro, C.G., Redpath, G.T., and Hussaini, I.M. (2009). ADAM-10-mediated N-cadherin cleavage is protein kinase C-alpha dependent and promotes glioblastoma cell migration. J. Neurosci. 29, 46054615.
  • Komuro, A., Imamura, T., Saitoh, M., Yoshida, Y., Yamori, T., Miyazono, K., and Miyazawa, K. (2004). Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1). Oncogene 23, 69146923.
  • Krasagakis, K., Garbe, C., Zouboulis, C.C., and Orfanos, C.E. (1995). Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res. 139, 169182.
  • Krasagakis, K., Kruger-Krasagakes, S., Fimmel, S., Eberle, J., Tholke, D., von der Ohe, M., Mansmann, U., and Orfanos, C.E. (1999). Desensitization of melanoma cells to autocrine TGF-beta isoforms. J. Cell. Physiol. 178, 179187.
  • Kreizenbeck, G.M., Berger, A.J., Subtil, A., Rimm, D.L., and Gould Rothberg, B.E. (2008). Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol. Biomarkers Prev. 17, 949958.
  • Maeda, M., Johnson, K.R., and Wheelock, M.J. (2005). Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J. Cell Sci. 118, 873887.
  • Maretzky, T., Reiss, K., Ludwig, A., Buchholz, J., Scholz, F., Proksch, E., de Strooper, B., Hartmann, D., and Saftig, P. (2005). ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc. Natl. Acad. Sci. USA 102, 91829187.
  • Massague, J., Seoane, J., and Wotton, D. (2005). Smad transcription factors. Genes Dev. 19, 27832810.
  • Mochizuki, S., and Okada, Y. (2007). ADAMs in cancer cell proliferation and progression. Cancer Sci. 98, 621628.
  • Nakagawa, S., and Takeichi, M. (1998). Neural crest emigration from the neural tube depends on regulated cadherin expression. Development 125, 29632971.
  • Nelson, W.J., and Nusse, R. (2004). Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303, 14831487.
  • Peifer, M., and Polakis, P. (2000). Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. Science 287, 16061609.
  • Reed, J.A., McNutt, N.S., Prieto, V.G., and Albino, A.P. (1994). Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am. J. Pathol. 145, 97104.
  • Reiss, K., Maretzky, T., Ludwig, A., Tousseyn, T., de Strooper, B., Hartmann, D., and Saftig, P. (2005). ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. Embo J 24, 742752.
  • Rodeck, U., Nishiyama, T., and Mauviel, A. (1999). Independent regulation of growth and SMAD-mediated transcription by transforming growth factor beta in human melanoma cells. Cancer Res. 59, 547550.
  • Rosenthal, D.S., Shima, T.B., Celli, G., De Luca, L.M., and Smulson, M.E. (1995). Engineered human skin model using poly(ADP-ribose) polymerase antisense expression shows a reduced response to DNA damage. J. Invest. Dermatol. 105, 3843.
  • Schlingensiepen, K.H., Schlingensiepen, R., Steinbrecher, A., Hau, P., Bogdahn, U., Fischer-Blass, B., and Jachimczak, P. (2006). Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev. 17, 129139.
  • Schmitt, C.J., Franke, W.W., Goerdt, S., Falkowska-Hansen, B., Rickelt, S., and Peitsch, W.K. (2007). Homo- and heterotypic cell contacts in malignant melanoma cells and desmoglein 2 as a novel solitary surface glycoprotein. J. Invest. Dermatol. 127, 21912206.
  • Shi, Y., and Massague, J. (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685700.
  • Tang, Y., Liu, Z., Zhao, L., Clemens, T.L., and Cao, X. (2008). Smad7 stabilizes beta-catenin binding to E-cadherin complex and promotes cell-cell adhesion. J. Biol. Chem. 283, 2395623963.
  • Trabosh, V.A., Divito, K.A., B, D.A., Simbulan-Rosenthal, C.M., and Rosenthal, D.S. (2009). Sequestration of E12/E47 and suppression of p27KIP1 play a role in Id2-induced proliferation and tumorigenesis. Carcinogenesis 30, 12521259.
  • Ueno, H., and Weissman, I.L. (2006). Clonal analysis of mouse development reveals a polyclonal origin for yolk sac blood islands. Dev. Cell 11, 519533.
  • Van Belle, P., Rodeck, U., Nuamah, I., Halpern, A.C., and Elder, D.E. (1996). Melanoma-associated expression of transforming growth factor-beta isoforms. Am. J. Pathol. 148, 18871894.
  • Van Hoorde, L., Braet, K., and Mareel, M. (1999). The N-cadherin/catenin complex in colon fibroblasts and myofibroblasts. Cell Adhes. Commun. 7, 139150.
  • Windoffer, R., Borchert-Stuhltrager, M., and Leube, R.E. (2002). Desmosomes: interconnected calcium-dependent structures of remarkable stability with significant integral membrane protein turnover. J. Cell Sci. 115, 17171732.